Cardiopulmonary effects of three different anaesthesia protocols in cats.

To develop an alternative anaesthetic regimen for cats with cardiomyopathy, the cardiopulmonary effects of three different premedication-induction protocols, followed by one hour maintenance with isoflurane in oxygen: air were evaluated in six cats. Group I: acepromazine (10 microg/kg) + buprenorphine (10 microg/kg) IM, etomidate (1-2 mg/kg) IV induction. Group II: midazolam (1 mg/kg) + ketamine (10 mg/kg) IM induction. Group III: medetomidine (1.5 mg/m2 body surface) IM, propofol (1-2 mg/kg) IV induction. Heart rate, arterial blood pressure, arterial blood gases, respiration rate, and temperature were recorded for the duration of the experiment. In group I the sedative effect after premedication was limited. In the other groups the level of sedation was sufficient. In all groups premedication resulted in a reduced blood pressure which decreased further immediately following induction. The reduction in mean arterial pressure (MAP) reached statistical significance in group I (142+/-22 to 81+/-14 mmHg) and group II (153+/-28 to 98+/-20 mmHg) but not in group III (165+/-24 to 134+/-29 mmHg). Despite the decrease in blood pressure, MAP was judged to have remained within an acceptable range in all groups. During maintenance of anaesthesia, heart rate decreased significantly in group III (from 165+/-24 to 125+/-10 b.p.m. at t=80 min). During anaesthesia the PCO2 and PO2 values increased significantly in all groups. On the basis of the results, the combination acepromazine-buprenorphine is preferred because heart rate, MAP, and respiration are acceptable, it has a limited sedative effect but recovery is smooth.

The effect of intravenous medetomidine on pupil size and intraocular pressure in normotensive dogs.

Medetomidine, a highly specific alpha-2 adrenergic agonist, has been demonstrated to lower intraocular pressure (IOP) in rabbits and cats when applied topically. The purpose of this study was to assess the influence of intravenously injected medetomidine on the pupil size (PS) and the IOP of non glaucomatous dogs. IOP was measured by applanation tonometry and PS was measured using Jameson calipers at t=0 (or time of IV injection of medetomidine (Domitor; Orion) at the dose of 1500 microg/m2 body surface area) and again after 5 minutes (t=5). The IV administration of medetomidine caused miosis in all 14 dogs. The mean PS decreased from 9.0 to 4.0 mm (p<0.001). The IOP was lowered in 10 dogs and in 4 dogs there was a rise in IOP. The mean IOP (mmHg) decreased from 22 to 21 (p>0.2). The data presented above confirm that medetomidine at a dose of 1500 microg/m2 body surface area produces miosis in non glaucomatous dogs, without influencing the IOP.